Frimley NHS trust pioneers treatment for thyroid eye disease
A Surrey health trust says it is to become the first in the UK to trial a drug for a debilitating eye condition.Frimley Health NHS Foundation Trust has recruited its first patient for a weekly injection to tackle thyroid eye disease.Caused by an overactive thyroid gland, the disease can cause eyes to feel dry and gritty, become bulging and swollen and sensitive to light, and can lead to blurred or double vision, according to the NHS.The new treatment will involve patients injecting themselves with pre-prepared syringes over the course of 24 weeks, rather than having to make regular visits to hospital.
The drug being trialled, Efgartigimod, reduces the antibodies thought to trigger the disease.Dr Anuradha Jayaprakasam, consultant ophthalmologist and principal investigator for the research study, said she had seen the "devastating side effects" of the condition."Rather than dealing with the problems that have happened, they can have a drug such as this which would prevent the condition escalating," she said. "The drug has the potential to impact on all aspects of the disease, including the appearance changes, and potentially prevent the disease advancing to the level of sight loss."It is a great motivation for me to be involved in work that could change the course of the disease for many of our patients."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
16-06-2025
- BBC News
Muscular dystrophy drug rejected for use by NICE
A man with a rare muscle-wasting condition said he feels "deflated" that a drug that improves his symptoms has not been approved for use on the Stephenson, from Doncaster, has myasthenia gravis and has been admitted to hospital 32 times because muscles involved in his breathing stopped since taking the drug efgartigimod, the 45-year-old has not needed to go on a ventilator once and said he had seen a "huge improvement" in his National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its "substantial" cost of more than £6,500 per infusion vial, despite it improving people's symptoms. Myasthenia gravis causes fatigue and muscle weakness, double vision, slurred speech, and difficulty with chewing, swallowing and making facial expressions."If you weigh up the cost of the drug against the hospitalisations, invasive procedures, surgeons and one-to-one care I have needed at times - I think prevention [with efgartigimod] is a cost-effective option," Mr Stephenson said."This is the first drug which has made a huge improvement and, unless you are a multimillionaire, you are not going to be able to afford to get it." 'Immense relief' Mr Stephenson was diagnosed in 2003 when, after leaving the armed forces, he began to struggle to exercise, close his eyes or smile."Food would get stuck in my throat and I would have to reach down and pull it out," he said."When I was drinking, I was choking, and water was pouring out of my nose."You worry, 'how am I going to live like this, what am I going to do?'"The father-of-four's symptoms fitted in with a recent car crash, but physiotherapists referred him to a neurologist who tested for the Stephenson said: "The diagnosis was an immense relief."If you have a chronic illness, it's good to learn about it, because you're going to be stuck with it forever."Adults who took part in a trial for efgartigimod reported regaining the ability to walk daily, dress independently, and some returned to work or education."Anybody who is on the drug at the minute can stay on it, but for new patients, it's not going to be available to them."I feel so lucky to be on it," Mr Stephenson said."I feel honoured and privileged to have been on the trial."Doctors will be able to privately prescribe the drug, also known as Vyvgart, meaning patients who can pay for it will still be able to to drug company Argenx, the price for one 400mg infusion vial is £6, number of vials used for one infusion, which Mr Stephenson said he has fortnightly, depends on the individual. 'Disheartening message' Andy Fletcher, chief executive of charity Muscular Dystrophy UK, said the decision not to approve the drug for NHS use "sends a disheartening message to those affected by rare and complex conditions"."Treatments are within their grasp, but their needs are not being prioritised," he said efgartigimod was an add-on alongside other treatments, rather than a appealed against the decision on the basis that the drug is a replacement, but NICE rejected the appeal."They got ignored and that, for everybody, was so frustrating," Mr Stephenson said."Our story should've made some sort of impact, but it feels it got bypassed and overlooked."NICE said drugs like efgartigimod replace other treatments only temporarily, providing "small benefits".A spokesperson said effective and fast-acting treatments like efgartigimod would be "welcomed" by patients, given the side effects and slow-acting nature of current treatments, but NICE could not justify the cost."The cost-effectiveness estimates [for efgartigimod] are substantially above what NICE considers an acceptable use of NHS resources," they said."We know this decision will be disappointing for people living with this debilitating condition and those who care for them."Muscular Dystrophy UK said Wales and Northern Ireland tend to follow NICE guidance, meaning patients there will most likely also be affected.A separate decision process is under way in Scotland. Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North
BBC News
25-04-2025
- BBC News
Frimley NHS trust pioneers treatment for thyroid eye disease
A Surrey health trust says it is to become the first in the UK to trial a drug for a debilitating eye Health NHS Foundation Trust has recruited its first patient for a weekly injection to tackle thyroid eye by an overactive thyroid gland, the disease can cause eyes to feel dry and gritty, become bulging and swollen and sensitive to light, and can lead to blurred or double vision, according to the new treatment will involve patients injecting themselves with pre-prepared syringes over the course of 24 weeks, rather than having to make regular visits to hospital. The drug being trialled, Efgartigimod, reduces the antibodies thought to trigger the Anuradha Jayaprakasam, consultant ophthalmologist and principal investigator for the research study, said she had seen the "devastating side effects" of the condition."Rather than dealing with the problems that have happened, they can have a drug such as this which would prevent the condition escalating," she said. "The drug has the potential to impact on all aspects of the disease, including the appearance changes, and potentially prevent the disease advancing to the level of sight loss."It is a great motivation for me to be involved in work that could change the course of the disease for many of our patients."
BBC News
15-04-2025
- BBC News
Frimley Park Hospital patients call for extra parking
Patients say a new extension to Frimley Park Hospital is "pretty pointless" without additional parking Health NHS Foundation Trust opened an extension to the site in April, adding diagnostic facilities and 74 new Baker told the Local Democracy Reporting Service the lack of parking "makes visits very stressful".The NHS trust said it plans to add 40 new parking spaces at the site in 2025 and the new wards provide "much-needed extra capacity". A spokesperson added: "Emergency situations can lead to unpredictable spikes in visitors and so we always advise patients and visitors to consider all travel options, including public transport and planning enough time ahead of appointments."The £49m extension took 16 months to complete and will also include a dedicated breast care outpatient unit once it is fully open later in 2025. 'It's so stressful' While hospital users have welcomed the extension, others have raised concerns about insufficient parking Cross said the extra capacity is "pretty pointless if you can't park anywhere"."Every time I have an appointment at this hospital it's so stressful trying to park," he said."It just adds to the stress of being unwell and having to go to the hospital."Mandi Coxall agreed there were "not enough spaces before this was built". The hospital's planned parking upgrades include LED lighting, improved bay markings, and additional drop off bays, in addition to the extra Trust said in March that new spaces will be available once the new lighting is installed, expected to be between June and August. The government has pledged to start rebuilding Frimley Park Hospital at a cost of up to £2bn by 2030, as about two thirds of the building is made from unstable reinforced autoclaved aerated concrete (Raac).A site for the replacement hospital is expected to be announced in May.
